Skripsi
KORELASI KADAR ALPHA-FETOPROTEIN DENGAN GAMBARAN CT-SCAN KONTRAS TIGA FASE PADA PASIEN HEPATOMA DI RSUP DR. MOHAMMAD HOESIN PALEMBANG TAHUN 2022 – 2023
Background: Hepatoma, or hepatocellular carcinoma, is the primary liver tumor accounting for 90% of liver tumor cases. In certain cases, hepatoma patients only undergo laboratory examinations without radiological imaging. An alternative method is needed to monitor tumor progression, predict patient prognosis, and determine appropriate treatment without radiological examinations, namely by measuring Alpha-Fetoprotein (AFP) levels. This study aims to determine whether there is a correlation between AFP levels and three-phase contrast CT-Scan finding in hepatoma patients at Dr. Mohammad Hoesin General Hospital Palembang. Methods: This study is an observational analytic research with a cross-sectional design. It uses secondary data from medical records, including gender, age, domicile, AFP, ALT, AST, direct bilirubin, indirect bilirubin levels, and three-phase contrast CT-Scan results covering nodule size, nodule number, and metastasis status, from hepatoma patients hospitalized in Dr. Mohammad Hoesin General Hospital Palembang from January 2022 to December 2023 who met the inclusion and exclusion criteria. Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 22. Results: A total of 71 samples met the inclusion criteria and did not meet the exclusion criteria. Based on univariate analysis, most samples were male (83.1%), aged 50–59 years (35.2%), living outside Palembang (67.6%), with elevated ALT (59.2%), AST (94.4%), direct bilirubin (91.8%), indirect bilirubin (54.1%), AFP ≥ 200 ng/mL (77.5%), nodule size ≥ 30 mm (87.3%), multiple nodules (67.6%), and no extrahepatic metastasis (74.6%). Bivariate analysis showed a significant correlation between AFP levels and nodule size on three-phase contrast CT-Scan finding (p-value = 0.031). Conclusions: There is a significant correlation between AFP levels and three-phase contrast CT-Scan finding in hepatoma patients at Dr. Mohammad Hoesin Palembang General Hospital in 2022 – 2023.
No other version available